Several Neisseria gonorrhoeae (NG) nucleic acid amplification tests (NAATs) exist with high sensitivity. However, specificity of NG NAAT testing may be suboptimal, particularly in extragenital biospecimens. Consequently, confirmation with a second NAAT is common, although represents a burden on resources. Furthermore, the rationale for confirmation is contentious.
Introduction
The management of Neisseria gonorrhoeae (NG) infection represents an increasing and significant clinical burden, in various settings including the UK. ln Scotland in 2017 there were 2610 episodes of gonorrhoea, in comparison with only 1073 cases in 2008 (1) . Similar observations of an increase over the last decade have also been noted in England. (2) Quantifying the magnitude of the increase as a result of changed sexual behaviours and/or shortfalls in management approaches is confounded by variability in indications for testing and the increased use of highly sensitive nucleic acid amplification tests (NAAT). Consistency of recommendations for testing-practice and application of robust NAATs can support the more accurate measurement of genuine trends. Certainly, NAAT rather than culture of NG is recommended as a first line test and an increasing diversity of molecular tests exists. Assaydriven influences in NAAT confirmation of NG have been reported including in a recent UK study where 27% of samples from females did not confirm with a second line test (3) . These data reconcile with those from a study by Vyth et al (2016) who reported that assay-choice significantly influenced the likelihood of culture confirmation (4) .
Guidance for the application of NG NAATs is available with the purpose of harmonising approach to support practically achievable, meaningful and technically-robust testing. Such guidance includes that from Public Health England (PHE) which recommends confirmatory testing of all extra-genital samples, with an assay that targets a different sequence from the initial assay in order to enhance specificity (5) . The same guidelines stipulate that "laboratories should only issue positive test results that are confirmed by supplementary testing or, for genital samples, where the positive predictive value (PPV) of the initial NAAT has been validated in the local laboratory as being ≥90%". The British Association for Sexual Health and HIV (BASHH, 2011) offer similar advice on confirmatory testing including the requirement for confirmation of extra-genital samples (6) . Guidance on confirmatory testing has also been issued by the Centre for Disease Control CDC (2014) which stipulate that repeat testing of NAAT-positive genital tract specimens is not recommended (if the screening assay is FDA approved) "because the practice does not improve the positive predictive value of the test" (7). For extra-genital sites the guidance indicates that in-house validation to CLIA standards is sufficient. This all said, how closely real-life practice follows guidance is not documented. Confirmatory testing of validated genital samples occurs and this is not exclusive to those laboratories where the initial NAAT has been confirmed to have a PPV of <90%. Furthermore, as described, NAATs continue to evolve and improve; whether confirmatory testing, including that associated with samples from extra-genital sites is needed requires evidence-based assessment. This consideration is made relevant by the fact that confirmatory testing does not represent a trivial resource implication for the laboratory.
The evolution of NG NAATs, the increased diversity of biospecimens tested in service laboratories and the disconnectedness and vintage of the guidelines justifies further detailed interrogation of the value of NG NAAT confirmation in large, population based, data series. The objective of the present work was to determine the level of NG confirmation in over 13,000 samples representing various biospecimen types from males and females and sent to a reference laboratory facility for routine confirmation via in-house PCR. Variables which influenced confirmation were subsequently detemined.
Material and Methods

Context and dimensions of sample
Currently, NG testing in Scotland is recommended only for groups where the prevalence is likely to be greater or equal to 1%, in line with national guidelines. The Scottish Bacterial STI reference laboratory provides a centralised, national service of NG NAAT confirmation for Scottish Health Boards (8) . The timeframe under study relates to samples received between Jan 2009 to June 2016.
Confirmation testing
The reference, confirmatory test was based on an in house approach which involved two multiplex real-time PCR methods, each incorporating an extraction inhibition control (phocine herpes virus-1) and a target specific for N. gonorrhoeae (porA and 16S rRNA genes). Samples (urine or swab eluate) were concentrated by centrifugation of 1 ml at 20,000 g for 5 min, then discarding 800 µl supernatant. Extraction of the samples was by The first line assay targeted the porA gene (Whiley, 2005) , with a limit of detection of around 10 copies/ml in swab eluate and 100 c/ml in urine samples (9) . The second line assay targeted the 16S rRNA gene to detect porA-negative strains. This method was developed inhouse. Although the primers were found to bind to other non-gonococcal Neisseria species, the probe was specific to N. gonorrhoeae. Therefore this assay may lead to false-negative results where non-gonococcal Neisseria are present, such as the pharynx Note that no further adjudication with .an additional assay was performed if there was discordance between the screening assay and the reference test. To determine what factors were predictive of confirmation for each screening assay individually, a logistic regression was performed using sex (male/female), whether the samples was validated (yes/no) and specific sample site/type. Year the samples was submitted (2009-2016 -treated as a continuous variable) was also included to serve as a proxy for the potential influence of assay version-change over time which was not available in the data set. Additionally, arguably sample year provides potential insight into the significance other factors within general lab testing environment that may have changed over time. Where any variables were found to not to be statistically significant they were sequentially removed to generate a final model containing only those variables which reached statistical significance at the 5% level. For the purpose of the regression, any sample with unknown sex and/or whether unvalidated vs validated status could not be confirmed was removed. The small number eye swabs (n=11) led to their removal for the regression analysis. Respective values for the Roche assay were 80.5% and 85.5% for female and male samples.
Measuring agreement of screening vs confirmation test and identification of significant
Results
Description of samples
Finally for the BD assay 58% of female samples confirmed vs 70.1% of male samples.
As expected specimen type/site and validation status did influence likelihood of confirmation. For formally validated (by the manufacturer) specimens, confirmation was evident in 96.2%; (95% CI: 95.7 -96.6), 86.0% (95% CI: 83.7 -88.1) and 73.9% (95% CI: 70.8 The sample type, least likely to confirm was an eye swab at 54.5%; (95% CI: 28.0 -78.7) with the caveat that only 11 were submitted for confirmation.
Which factors are significantly associated with confirmation?
Variables that were identified as significant are included in Table 4 . Factors influencing confirmation of the Abbott assay were that samples from females were more likely to confirm. Additionally a small year on year reduction in likelihood of confirmation was observed. Finally, cervical, rectal, urethral and urine samples were all more likely to confirm compared to vulval samples.
The only factor that was associated with confirmation with the Roche assay was sample 
Discussion
The increase in NG infection and the implications of this necessitate swift and accurate diagnosis to support and inform both epidemiological assessment and crucially, appropriate clinical support and management. The need for confirmation requires review so that resources can be used equitably and efficiently. In this evaluation we observed that the two most commonly applied first line tests for NG in Scotland showed high concordance with a secondary reference test performed in a centralised reference laboratory and exceeded (Abbott) or approached (Roche) 90%. This puts into question the additional value that is gained via confirmation of samples initially tested with these assays particularly with respect to validated samples (10, 11) Of interest confirmation of rectal swabs (the second most common non-validated specimen received), exceeded 90% for the Roche and Abbott assay and was 87% for the BD, which was actually higher than confirmation associated with certain validated samples for the latter assay. These data are consistent with those in an earlier study by Perry et al (2014) who concluded that rectal NG positives generated by the Roche 4800 assay did not require confirmation when compared to an opa/pap duplex assay (12) . While the conclusions of Certainly the present work has demonstrated that assay type can drive discordance, so specific evaluation of other and novel assays is warranted when considering whether confirmation is required. This said, it would appear that the current state of the art of commercial NG assays is promising. A recent article by Causer et al (2018) showed a reassuring level of concordance between point of care (POC) testing with the Xpert CT/NG assay (Cepheid, Wooburn Gree, UK) vs standard of care. In this study, overall concordance for NG detection was 99.9% with positive concordance of 100.0% and negative concordance of 99.9% (13) . Clearly, POC testing does not rely on confirmation of the result at a reference laboratory and growing interest in POC is evident in new technologies and quality processes to support this approach (14 -16) .
There are limitations to the study, as indicated, we accept that there are an increasing number of NG assays available and in the present study, we evaluated only three platforms. Furthermore, the most common screening assay applied was the Abbott test by some margin meaning that as a function of its larger sample size, smaller differences (in confirmation) were more likely to be significant when compared to the other two assays. In addition we accept that any reference/confirmatory test is not itself impervious to error.
However the strengths of the study are the large overall denominator which allowed assessment of concordance according to several variables including specific sample site/biospecimen type -and the fact that the demographic was population-based given that samples were sent from across Scotland as part of a routinely offered service.
To conclude, the level of confirmation with NG screening assays and an in house reference assay was high and exceeded or approached 90% for the two most commonly used assays in Scotland in validated samples. The rationale for confirmatory testing of validated samples tested by the Abbott and Roche assays is therefore not supported. In addition rectal swabs appear to constitute robust bio-specimens for NG testing and confirmatory testing may not be justified. 
